GlassScriptPhysician profile
Daniel Craig Citron
NPI 1861442410
$8,073.99
in general payments reported to CMS, 2019-2025
46 companies · $1,003 in 2025
The $1,003 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $747 · 2020: $1,002 · 2021: $1,008 · 2022: $1,317 · 2023: $1,613 · 2024: $1,384 · 2025: $1,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,906 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,906.04 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,576.39 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $618.08 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $617.31 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $562.86 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Astrazeneca Pharmaceuticals LP | $482.13 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Astellas Pharma US INC | $455.81 | 2021-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $410.84 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $379.80 | 2019-2024 | Xarelto, Spravato |
| Allergan, INC. | $318.19 | 2019-2020 | |
| Amgen INC. | $310.25 | 2019-2025 | Repatha, Otezla, Prolia |
| Esperion Therapeutics, INC. | $287.40 | 2021-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $230.48 | 2019-2025 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Novartis Pharmaceuticals Corporation | $221.02 | 2020-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $184.63 | 2019-2023 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $171.78 | 2022-2025 | Caplyta |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Citron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.